Market News

NASDAQ:LGVN News

8 stories
globenewswire

Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors

Dr. Ascheim has over 30 years of clinical and executive experience advancing breakthrough therapies, including gene, cell, and biologicsJoshua HareDeborah D. Ascheim, M.D.MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. NASDAQ:LGVN a clinical stage biotechnology company developing cellular…

GlobeNewswire en
StocksUS
globenewswire

Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease

Joshua HareMIAMI, July 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. NASDAQ:LGVN, a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical…

GlobeNewswire en
StocksUS
tradingview

Longeveron grants equity awards to Executive Chairman for March 2026 financing

Longeveron granted special equity awards to its Executive Chairman on July 6, 2026, recognizing his role in the March 2026 financing and for continued service.Original SEC Filing: Longeveron Inc. [ LGVN ] - 8-K - Jul. 08, 2026This is an AI-powered summary. It may contain inaccuracies. Consider veri…

TradingView en
StocksUS
tradingview

Marie Washburn named CFO at Longeveron; Dr. Arjun "JJ" Desai joins Longeveron board

Longeveron appointed Marie Washburn as Senior Vice President and Chief Financial Officer effective July 13, 2026, and added Dr. Arjun “JJ” Desai to its Board as a Class III director effective July 2, 2026.Original SEC Filing: Longeveron Inc. [ LGVN ] - 8-K - Jul. 06, 2026This is an AI-powered summa…

TradingView en
StocksUS